- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06064097
- Original retssag
En undersøgelse, der bruger et nyt lægemiddel, Nivolumab, i kombination med kemoterapi til behandling af en type kræft kaldet nasopharyngeal carcinoma (NPC)
Et fase 2-studie med kemoimmunterapi med gemcitabin, cisplatin og nivolumab i nydiagnosticeret nasopharyngeal carcinom (NPC)
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
- Andet: Quality-of-Life Assessment
- Medicin: Cisplatin
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Andet: Questionnaire Administration
- Procedure: Echocardiography Test
- Procedure: Multigated Acquisition Scan
- Procedure: Positron Emission Tomography
- Biologisk: Nivolumab
- Medicin: Gemcitabine
- Procedure: Biopsy Procedure
- Procedure: Chest Radiography
- Andet: Electronic Health Record Review
- Stråling: Radiation Therapy
- Procedure: Biospecimen Collection
- Andet: Fluciclovine F18
- Procedure: X-Ray Imaging
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor, blood and stool) for future research studies.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy, blood and stool sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australien, 2310
- Rekruttering
- John Hunter Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: (02) 4985 5180
-
Ledende efterforsker:
- Kristy McCarthy
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Rekruttering
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-mail: research4kids@ucalgary.ca
-
Ledende efterforsker:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Ledende efterforsker:
- Sarah J. McKillop
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-mail: ask.CRS@sickkids.ca
-
Ledende efterforsker:
- Avram E. Denburg
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Rekruttering
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-mail: info@thechildren.com
-
Ledende efterforsker:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- Centre Hospitalier Universitaire Sainte-Justine
-
Ledende efterforsker:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Rekruttering
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Ledende efterforsker:
- Stephanie Vairy
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Ledende efterforsker:
- Jamie M. Aye
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016
- Rekruttering
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Ledende efterforsker:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72202-3591
- Rekruttering
- Arkansas Children's Hospital
-
Ledende efterforsker:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Downey, California, Forenede Stater, 90242
- Rekruttering
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Ledende efterforsker:
- Robert M. Cooper
-
Loma Linda, California, Forenede Stater, 92354
- Rekruttering
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Ledende efterforsker:
- Albert Kheradpour
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
Ledende efterforsker:
- Rachana Shah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Madera, California, Forenede Stater, 93636
- Rekruttering
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Ledende efterforsker:
- Ruetima Titapiwatanakun
-
Oakland, California, Forenede Stater, 94611
- Rekruttering
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Ledende efterforsker:
- Aarati V. Rao
-
Oakland, California, Forenede Stater, 94609
- Rekruttering
- UCSF Benioff Children's Hospital Oakland
-
Ledende efterforsker:
- Jennifer G. Michlitsch
-
Kontakt:
- Site Public Contact
- Telefonnummer: 510-428-3264
- E-mail: PedOncRschOAK@ucsf.edu
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Ledende efterforsker:
- William D. Roberts
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Ledende efterforsker:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Children's Hospital Colorado
-
Ledende efterforsker:
- Navin R. Pinto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Rekruttering
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Ledende efterforsker:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
- Rekruttering
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Children's National Medical Center
-
Ledende efterforsker:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Ledende efterforsker:
- Brian Stover
-
Jacksonville, Florida, Forenede Stater, 32207
- Rekruttering
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
Miami, Florida, Forenede Stater, 33155
- Rekruttering
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Ledende efterforsker:
- Ziad A. Khatib
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Ledende efterforsker:
- Zhongbo Hu
-
Orlando, Florida, Forenede Stater, 32827
- Rekruttering
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
Pensacola, Florida, Forenede Stater, 32504
- Rekruttering
- Nemours Children's Clinic - Pensacola
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Ledende efterforsker:
- Jeffrey H. Schwartz
-
Tampa, Florida, Forenede Stater, 33607
- Rekruttering
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Ledende efterforsker:
- Don E. Eslin
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Ledende efterforsker:
- Sarah G. Mitchell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Lurie Children's Hospital-Chicago
-
Ledende efterforsker:
- Amy L. Walz
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Chicago, Illinois, Forenede Stater, 60637
- Suspenderet
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Ledende efterforsker:
- Marissa Just
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Ikke rekrutterer endnu
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Ledende efterforsker:
- James T. Badgett
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70118
- Rekruttering
- Children's Hospital New Orleans
-
Ledende efterforsker:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
-
Maine
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Ledende efterforsker:
- Aaron R. Weiss
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Ledende efterforsker:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Ledende efterforsker:
- Allison F. O'Neill
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Ledende efterforsker:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Rekruttering
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Ledende efterforsker:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- Children's Mercy Hospitals and Clinics
-
Ledende efterforsker:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Frederick S. Huang
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Rekruttering
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Ledende efterforsker:
- Jill C. Beck
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Ledende efterforsker:
- Jill C. Beck
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Ledende efterforsker:
- Katharine Offer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Neptune City, New Jersey, Forenede Stater, 07753
- Rekruttering
- Jersey Shore Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-776-4240
-
Ledende efterforsker:
- Katharine Offer
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Ledende efterforsker:
- Scott Moerdler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Newark, New Jersey, Forenede Stater, 07112
- Rekruttering
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Ledende efterforsker:
- Teena Bhatla
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Rekruttering
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Ledende efterforsker:
- Lauren R. Weintraub
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Ledende efterforsker:
- Alice Lee
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Ledende efterforsker:
- Joel A. Kaplan
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Medical Center
-
Ledende efterforsker:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Forenede Stater, 27834
- Rekruttering
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Ledende efterforsker:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Ledende efterforsker:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58122
- Rekruttering
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Ledende efterforsker:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-mail: cancer@cchmc.org
-
Ledende efterforsker:
- Brian K. Turpin
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Ledende efterforsker:
- Duncan S. Stearns
-
Columbus, Ohio, Forenede Stater, 43205
- Rekruttering
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Ledende efterforsker:
- Mark A. Ranalli
-
Dayton, Ohio, Forenede Stater, 45404
- Rekruttering
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Ledende efterforsker:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Ledende efterforsker:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Rekruttering
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Ledende efterforsker:
- Jacob A. Troutman
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Penn State Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-6012
-
Ledende efterforsker:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Ledende efterforsker:
- Theodore W. Laetsch
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Ledende efterforsker:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Rekruttering
- Prisma Health Richland Hospital
-
Ledende efterforsker:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Forenede Stater, 29605
- Rekruttering
- BI-LO Charities Children's Cancer Center
-
Ledende efterforsker:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Rekruttering
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Ledende efterforsker:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- Rekruttering
- Saint Jude Children's Research Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-226-4343
- E-mail: referralinfo@stjude.org
-
Ledende efterforsker:
- Catherine G. Lam
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Ledende efterforsker:
- Scott C. Borinstein
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Ledende efterforsker:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Forenede Stater, 78723
- Rekruttering
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Ledende efterforsker:
- Shannon M. Cohn
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Avanthi T. Shah
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Ledende efterforsker:
- Chelsee Greer
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-mail: burton@bcm.edu
-
Ledende efterforsker:
- Mehmet F. Okcu
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Ledende efterforsker:
- Najat C. Daw
-
San Antonio, Texas, Forenede Stater, 78207
- Rekruttering
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Ledende efterforsker:
- Julie Voeller
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Ledende efterforsker:
- Brian C. Belyea
-
Norfolk, Virginia, Forenede Stater, 23507
- Rekruttering
- Children's Hospital of The King's Daughters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Ledende efterforsker:
- Melissa S. Mark
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- VCU Massey Comprehensive Cancer Center
-
Ledende efterforsker:
- Madhu S. Gowda
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Ledende efterforsker:
- Sarah E. Leary
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-mail: research@multicare.org
-
Ledende efterforsker:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Children's Hospital of Wisconsin
-
Ledende efterforsker:
- Angela Steineck
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
-
-
-
-
Christchurch, New Zealand, 8011
- Rekruttering
- Christchurch Hospital
-
Ledende efterforsker:
- Tristan Pettit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 03 364 0640
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1145
- Rekruttering
- Starship Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 0800 728 436
-
Ledende efterforsker:
- Leander D. Timothy
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekruttering
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Ledende efterforsker:
- Maria E. Echevarria
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
1 to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female) 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female) 6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
Andre navne:
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo tissue biopsy
Andre navne:
Undergo chest x-ray
Andre navne:
Ancillary studies Receive radiation therapy
Andre navne:
Undergo blood and stool sample collection
Andre navne:
Given IV
Andre navne:
Undergo dental x-ray
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
Tidsramme: Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events. IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event-free survival (EFS)
Tidsramme: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
Tidsramme: At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
Tidsramme: At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
Tidsramme: Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EFS
Tidsramme: At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
Tidsramme: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
Tidsramme: At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
Tidsramme: Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
Tidsramme: Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
Tidsramme: Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
Tidsramme: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
Tidsramme: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
Tidsramme: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Robyn D Gartrell, Children's Oncology Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Stomatognatiske sygdomme
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Karcinom
- Otorhinolaryngologiske sygdomme
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Nasopharyngeale sygdomme
- Pharyngeale sygdomme
- Nasopharyngeale neoplasmer
- Nasopharyngealt karcinom
- Aminosyrer, peptider og proteiner
- Proteiner
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Fysiske fænomener
- Udstyr og forsyninger
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Metaller, tung
- Platinforbindelser
- Elektromagnetiske fænomener
- Magnetiske fænomener
- Overgangselementer
- Elektromagnetisk stråling
- Stråling, ioniserende
- Nivolumab
- Gemcitabin
- Cisplatin
- 1,2-diaminocyclohexanplatin II-citrat
- Strålebehandling
- Stråling
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Platinum
- Røntgenstråler
- Fantomer, billeddannelse
- Fluciclovine F-18
Andre undersøgelses-id-numre
- NCI-2023-07208
- U10CA180886 (U.S. NIH-bevilling/kontrakt)
- NCI-2023-07208 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- ARAR2221 (Anden identifikator: CTEP)
- ARAR2221 (Anden identifikator: Children's Oncology Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .